ãªãã¯ãã³æ ªãè¦ã¤ãã£ã¦ãããããæ°é±éã§ãææè ã¯ä¸çä¸ã«åºãã£ã¦ãã¾ãã ãã®éã«ãªãã¯ãã³æ ªã«é¢ããå¤ãã®ç¥è¦ãéã¾ã£ã¦ãã¾ããã ãªãã¯ãã³æ ªã®ç¾æç¹ã§ã®åºããã¯ï¼ãªãã¯ãã³æ ªãæ¤åºããã¦ããå½ãå°åï¼GISAIDããï¼ ãªãã¯ãã³æ ªã«ããææè ã¯ä¸çä¸ã§æ¡å¤§ãç¶ãã¦ãã¾ãã 2021å¹´12æ10æ¥æç¹ã§ã62ã«å½2382人ã®ãªãã¯ãã³æ ªã«ããææè ãå ±åããã¦ãã¾ãã æ¥æ¬ã§ã¯ããã¾ã§ã«12ä¾ãå ±åããã¦ãã¾ãããã¹ã¦æ¤ç«ã§è¦ã¤ãã£ããã®ã§ãããå½å ã§ã®ææä¾ã¯ã¾ã ããã¾ããã ããããã¢ã¡ãªã«ãã¤ã®ãªã¹ããã«ã®ã¼ããã³ãã¼ã¯ãã¹ãã¤ã³ãã¢ã¤ã¹ã©ã³ãã§ã¯ãã§ã«å½å ææä¾ã¨èããããäºä¾ãå ±åããã¦ãããä»å¾ã®ãããªãæ¡å¤§ãæ¸å¿µãããç¶æ³ã§ãã ã¤ã®ãªã¹ã§ã¯12æä¸æ¬ã«ã¯ãªãã¯ãã³æ ªããã«ã¿æ ªãä¸åã試ç®ã¤ã®ãªã¹ã§5çä¾ç®ãå ±åããã¦ããã®æ¥æ°ã¨ããããã®å¤ç°æ ªææè ã®æ¨ç§»ï¼UKH
ãã¼ã¹ã¿ã¼æ¥ç¨®ã®å¹æãå¯åå¿ãªã©ã®ãã¼ã¿ãå¾ã ã«æããã«ãªã£ã¦ãã¦ãããæ¥æ¬ã§ã9æ17æ¥ãããã¼ã¹ã¿ã¼æ¥ç¨®ã«é¢ããè°è«ãå§ã¾ãã¾ããã ç¾æç¹ã§ãã¼ã¹ã¿ã¼æ¥ç¨®ã«ã¤ãã¦åãã£ã¦ãããã¨ãã¾ã¨ãã¾ããã æ°åã³ããã¯ã¯ãã³ã®ææäºé²å¹æã¯çµæçã«ä½ä¸ããæ°åã³ããã¯ã¯ãã³ã«ããææäºé²å¹æã®æ¨ç§»ï¼ACIP "Framework for COVID-19 booster doses"ããï¼ ã¢ã¡ãªã«ã¯2020å¹´12æããæ°åã³ããã¯ã¯ãã³ã®æ¥ç¨®ãéå§ãã¾ããã å½åã90ï¼ ä»¥ä¸ã¨é«ãææäºé²å¹æãä¿ã£ã¦ãã¾ããããå¾ã ã«ãã®å¹æãè½ã¡ã¦ãã¦ãããã¨ãæããã«ãªã£ã¦ãã¾ããã 2021å¹´7æã«ã¯ãå¤ãã®ç ç©¶ã§ææäºé²å¹æã40ã80ï¼ ã¾ã§è½ã¡ã¦ãã¦ãã¾ãã ãã®è¦å ã¨ãã¦ãã¯ã¯ãã³æ¥ç¨®å¾ã«ä¸åæä½ãå¾ã ã«ä½ä¸ãã¦ãããã¨ãããã¦ãã«ã¿æ ªãæ¡å¤§ãã¦ãããã¨ãæãããã¾ãã æ¥æ¬å½å ã§ããè¤ç°å»ç§å¤§
æ°åã³ããã¦ã¤ã«ã¹ã«ææããå¾ã1ã¶æä»¥ä¸çç¶ãç¶ããã¨ããããå¾éºçãã¨å¼ã°ãã¦ãã¾ãã ç¾æç¹ã§å¾éºçã«ã¤ãã¦åãã£ã¦ãããã¨ã«ã¤ãã¦ãç´¹ä»ãã¾ãã æ°åã³ããã®ãå¾éºçãã¨ã¯ï¼æ°åã³ããã«ææãã人ã®ä¸ã«ã¯ãæ°é±ãæ°ã¶æéã«æ¸¡ã£ã¦æ§ã ãªçç¶ãç¶ãæ¹ããã¾ãã ãããã¯æµ·å¤ã§ã¯ãLONG COVIDããPost COVIDããªã©ã¨å¼ã°ãã¦ãã¾ãããæ¥æ¬å½å ã§ã¯ãå¾éºçãã¨å¼ã°ãããã¨ãå¤ããããããã§ãæ°åã³ããå¾éºçã¨ãã表ç¾ã使ãã¾ãã æ°åã³ããå¾éºçã®å®ç¾©ã¯å½å ã§ã¯å®ã¾ã£ããã®ã¯ããã¾ããããæµ·å¤ã§ã¯ãçºçãã4é±éçµã£ã¦ãç¶ãçç¶ããå¾éºçã¨å®ç¾©ãã¦ãããã®ãããã¾ãã æ°åã³ããå¾éºçã®åå ã¯ï¼æ°åã³ããå¾éºçãèµ·ããåå ã«ã¤ãã¦ã¯ã¾ã å¤ããæªè§£æã§ãã åä¸ã®ç æ ã§ã¯ãªãã4ã¤ã®ç æ ãè¤åçã«çµ¡ã¿åã£ãç æ ã§ã¯ãªãããã¨èãããã¦ãã¾ãã 4ã¤ã®ç æ ã¨ã¯ã (1) èºãå¿
ãèªå£²æ°èããæ°åã³ããã¦ã¤ã«ã¹ã®ãã¡ææãæ¡å¤§ãã¦ããã¤ã³ãç±æ¥ã®å¤ç°ã¦ã¤ã«ã¹ããã«ã¿æ ªãã«ã¤ãã¦ãç¹å®ã®å¤ç°ãåã¤å ããã¨ãç¾è¡ã®ã¯ã¯ãã³ã§ã§ããæä½ã®å¹æã大ããå¼±ã¾ãæããããã¨ããç ç©¶çµæãã大éªå¤§ã®ãã¼ã ãã¾ã¨ããããã¼
æ°åã³ããã¦ã¤ã«ã¹ã®ææççºãæ¢ã¾ããªãä¸ãã¯ã¯ãã³ã¸ã®ä¸ä¿¡æãèãããããã«ãªã£ã¦ãããã¯ã¯ãã³ããããééã£ãæ å ±ãªã©ãé¯ç¶ããä¸ã§ããã¾ããã¯ã¯ãã³ã®æ£ããç¥èãæã¤ãã¨ã®éè¦æ§ãå¢ãã¦ããã¨ããããåç·¨è¨äºï¼ãã³ããã¯ã¯ãã³ãåºããä¸ä¿¡ãã«ããã¾ããç¥ãã¹ãããã¡ã¤ã¶ã¼ã¨ã¢ãã«ãã®éãããmRNAã¯ã¯ãã³ã®å©ç¹ã¨æ¬ ç¹ãâ¦ï¼ãï¼ã§ã¯ãã¡ã¤ã¶ã¼ã¯ã¯ãã³ã¨ã¢ãã«ãã¯ã¯ãã³ã®éããã¯ã¯ãã³ã®ä¸é·æçãªå®å ¨æ§ãªã©ã«ã¤ãã¦ç´¹ä»ããããä»åã¯ããã«ææ°ã®ç ç©¶çµæãä¸æç´¹ä»ãããï¼æ¬è¨äºã¯8ææ«ç¾å¨ã®æ å ±ãåºã«å·çï¼ ã³ããã¯ã¯ãã³ãè¨åºè©¦é¨ã§ãããã£ãå¹æãæ¹ãã¦åçå´åçã§ã®æ¿èªæã«æåºãããè¨åºè©¦é¨ã§ã®æ°åã³ããã¯ã¯ãã³ã®å¹æãç´¹ä»ãããã 念ã®ããä»è¨ãã¦ããã¨ããã®ã¯ã¯ãã³ã®å³æ ¼ãªå¹æå¤å®ã¯ãæä½ç²å¾ããã確å®ã«ãªãã2åæ¥ç¨®å®äº14æ¥å¾ä»¥éããæã¾ããããç ç©¶ã«ãã£ã¦ã2åæ¥ç¨®å®äº7æ¥
Hiroshi Tsuji, MD, PhD, MPHðç£æ¥å» @Hiroshi_Tsuji ã»ã¹ãã¼ãã§ã¯ã100μm以ä¸ã®é£æ²«ã«å¯¾ãã¦ã100å-1000åã®100μmæªæºã®ã¨ã¢ãã¾ã«ãçæ ã»åä¾ã¯å¤§äººã«æ¯ã¹ã¦ã¦ã¤ã«ã¹ãå«ãã ã¨ã¢ãã¾ã«ã®çºçãå°ãªã ã»ããã¤ãã®å¼å¸å¨ç³»ã¦ã¤ã«ã¹ã対象ã¨ããç ç©¶ã§ã¯ã大ããªã¨ã¢ãã¾ã«ãããå°ããªï¼5μmæªæºï¼ã¨ã¢ãã¾ã«ã®ã»ããã¦ã¤ã«ã¹RNAãå¤ãã£ã 12/n 2021-08-27 17:22:32 Hiroshi Tsuji, MD, PhD, MPHðç£æ¥å» @Hiroshi_Tsuji ã»éæ¢ãã空æ°ä¸ã§ã¯ã5μmã®ã¨ã¢ãã¾ã«ã1.5mã®é«ãããå°é¢ã«æ²ãã®ã«33åããã ã»1μmã®ã¨ã¢ãã¾ã«ã¯12æé以ä¸ç©ºæ°ä¸ã«æµ®é 以ä¸ãããç©ºæ°ææã«ããææãããçè§£ããäºã§ã广çãªææå¯¾çãããæç¢ºã«ãªãã¨ç¤ºåãããã¨çµè« ã ãã¡ããã¡ã奥深ã
ä»ã®é½å ã®æ°åã³ããã¦ã¤ã«ã¹ç¦ã®ç¾ç¶ãåãã£ã¦ãªãæ¹ã«æ¹ãã¦äºæ ã説æããã¨ãå¼å¸å°é£ãåºãç¨ã®ç¶æ ã§ã250ç é¢ãæºåºã§åãå ¥ãã§ããé½å¤æ¬éãããåãå ¥ãã§ããã¨ããã人工å¼å¸å¨ãå ¨ã¦ä½¿ã£ã¦ããã®ã§ç¶æ æªåæã«ã人工å¼å¸å¨ç®¡çã¯ããèçããªããã¨ãæ¡ä»¶ã«åãå ¥ãã¦ãç¶æ ã§ãã
åæµ·éå ã§16æ¥ãæ°ãã«357äººã®æ°åã³ããã¦ã¤ã«ã¹ææã確èªãããã15æ¥ã¯366人ã§ãææè ã¯ç´¯è¨4ä¸9909人ã¨ãªã£ããè«å°ç§å¸ã®ã¢ã¤ã¹ããã±ã¼å¤§ä¼ã®å¤§è¦æ¨¡ã¯ã©ã¹ã¿ã¼ï¼ææè éå£ï¼ã35人å¢ãã¦è¨128人ã«ãªã£ãã»ããå½é¤¨å¸ã§æ°ããªã¯ã©ã¹ã¿ã¼ã3ä»¶çºçãããªã©ãå ¨éã§ææãåºãã£ã¦ããã15ã16両æ¥ã¨ãæ»è ã®â¦
ä¸çä¸ã§ææãæ¡å¤§ãã¦ããæ°åã³ããã¦ã¤ã«ã¹ææçï¼COVID-19ï¼ã§ãããå¦ç£å©¦ã¸ã®å½±é¿ã注ç®ããã¦ãããæ®µã ã¨ç ç©¶å ±åãèç©ããã¦ãã¦ãã¾ãã å¦å¨ ä¸ã®COVID-19çºçã«ããå¦å¨ ã¸ã®å½±é¿ã«é¢ããç ç©¶ã§ã¯ã6人ã«1人ãéçåãã4人ã«1äººãæ©ç£ã¨ãªã£ã¦ãã¾ãããæ»äº¡çã¯2ï¼ ã§ãéçåã®ãªã¹ã¯ã¨ãã¦è¥æºãå«ç æ´ãç³å°¿ç ãå¦å¨ é«è¡å§è çãªã©ãæãããã¦ãã¾ããï¼æç®ï¼ï¼ ï¼æ¥æ¬å½å ã ãã®ãã¼ã¿ã§ã¯ãªãããè§£éã«ã¯æ³¨æãè¦ãã¾ãããåèã«ãã¹ãéè¦ãªãã¼ã¿ã ã¨æãã¾ãã 䏿¹ã§ãå¦å¨ ä¸ã«æ°åã³ããã¦ã¤ã«ã¹ã«ææããå ´åã®ã赤ã¡ããã®å¥åº·ç¶æ ï¼æ°çå äºå¾ï¼ãã¸ã©ã®ãããªå½±é¿ãåºãã®ãã¯ãã¾ãã¯ã£ãããã¦ãã¾ããã§ããã ä»åã2021å¹´5æã«JAMAã¨ããå»å¦éèªã«æ²è¼ãããè«æãå ã«ããå¦å©¦ããã®æ°åã³ããã¦ã¤ã«ã¹ææã«ãããç£ã¾ãã赤ã¡ããã¸ã®å½±é¿ãã«ã¤ãã¦ããã£ã¦ãããã¨ãç´¹ä»ãã¾ã
ç¾å¨ãå°æ±æ¸ æäºåæè·å¡ã«ããã¦ãæ°åã³ããã¦ã¤ã«ã¹ææç齿§è ãè¤æ°ç¢ºèªããã¦ãã¾ãã ãã¿ã®åéä½å¶ãç¶æããããã«ãæ¸ æäºåæã§ã¯è·å¡ã®é ç½®ã工夫ããé常ã©ããã®å鿥åãã§ããããåªãã¦ãã¾ããããæ¥åã«å¿ è¦ãªè·å¡ã®ç¢ºä¿ãå°é£ã¨ãªã£ããããä¸è¨ã®æéã«ããã¦ãçãããªããã¿ï¼ä¸çãã¿ï¼ãã®åéã伿¢ãããã¾ãã åºæ°ã®çæ§ã«ã¯ã大å¤ãä¸ä¾¿ãããããããã¾ããããçè§£ã¨ãååããé¡ããããã¾ãã ãçãããªããã¿ï¼ä¸çãã¿ï¼ã®åé伿¢æéçã æéï¼8æ16æ¥ï¼æææ¥ï¼ãã8æ31æ¥ï¼ç«ææ¥ï¼ã¾ã§ 対象ï¼åºå ãã¹ã¦ã®å°åº â»çãããã¿ï¼å¯çãã¿ï¼ãè³æºãç²å¤§ãã¿ã¯ãé常ã©ããåéãè¡ãã¾ãã â»ä¸è¨ã«ã¤ãã¦ã¯ããã©ã·åã³åºå ±ãããã¨ãã8æ20æ¥å·ã§å¨ç¥ãããã¾ãã
ä½è¤ãä½³ï¼æ±äº¬å¤§å¦å»ç§å¦ç ç©¶æãé屿æçå½éç ç©¶ã»ã³ã¿ã¼ãã·ã¹ãã ã¦ã¤ã«ã¹å¦åéãåææï¼ â»ç ç©¶ã³ã³ã½ã¼ã·ã¢ã ãThe Genotype to Phenotype Japanï¼G2P-Japanï¼ãï¼æ³¨1ï¼ã¡ã³ãã¼ ä½è¤ãä½³ï¼æ±äº¬å¤§å¦å»ç§å¦ç ç©¶æãé屿æçå½éç ç©¶ã»ã³ã¿ã¼ãã·ã¹ãã ã¦ã¤ã«ã¹å¦åéãåææï¼ æ¬åãåå°ï¼çæ¬å¤§å¦ããã¬ããã¦ã¤ã«ã¹å¦å ±åç ç©¶ã»ã³ã¿ã¼ãææäºé²é¨éææå ç«å¦åéãè¬å¸«ï¼ ä¸å·ãèï¼æ±æµ·å¤§å¦ãå»å¦é¨å»å¦ç§ãåºç¤å»å¦ç³»ååçå½ç§å¦ãè¬å¸«ï¼ é½è¤ãæï¼å®®å´å¤§å¦ãè¾²å¦é¨ç£å»å¦ç§ãç£å»å¾®çç©å¦ç 究室ãåææï¼ æ± ç°ãè¼æ¿ï¼çæ¬å¤§å¦ããã¬ããã¦ã¤ã«ã¹å¦å ±åç ç©¶ã»ã³ã¿ã¼ãå½éå 端ç ç©¶é¨éååã¦ã¤ã«ã¹ã»éºä¼å¦åéåéãåææï¼ ä¸éãè²´å°ï¼çæ¬å¤§å¦ããã¬ããã¦ã¤ã«ã¹å¦å ±åç ç©¶ã»ã³ã¿ã¼ãææäºé²é¨éææå ç«å¦åéãææï¼ æ°åã³ããã¦ã¤ã«ã¹ã®ã¹ãã¤ã¯ã¿ã³ãã¯è³ªï¼æ³¨2ï¼ã®ææ
å³¶æ ¹çè¦å¯æ¬é¨ã¯ï¼ï¼æ¥ãçè¦æ¬é¨å æå±ã®ç·æ§è¦å¯å®ï¼äººãæ°åã³ããã¦ã¤ã«ã¹ã«ææããã¨çºè¡¨ãã¾ããã ï¼äººã¯ï¼ï¼ä»£ããï¼ï¼ä»£ã§ãå ¨å¡ãæ±äº¬ãªãªã³ããã¯ãã©ãªã³ããã¯ã®ç¹å¥æ´¾é£é¨éã¨ãã¦ãæ±äº¬ã«æ´¾é£ããã¦ããè¦å¯å®ã ã¨ãããã¨ã§ããï¼ï¼æ¥ã®æ¤æ»ã§é½æ§ã夿ãã¾ããã æ´¾é£ã®æéã¯ãï¼æä¸æ¬ããï¼æï¼æ¥ã¾ã§ã§ãï¼ï¼æ¥ã«ç§»åãã¦å³¶æ ¹çã«å¸°ã£ã¦ããã¨ãããã¨ã§ãã
åæã®ããé½å ã®å¤§å¦ç é¢ã§ã¯2æ¬¡ææ¥ã¯ææ¥è»å容å¾ç é¢æè¨ºãã¦ã40ä»¶ç¨åº¦æãããç¶æ ã3æ¬¡ææ¥ã20ä»¶ç¨åº¦æãããç¶æ ã§å°ã£ãææ¥éãåãã¨ããã«äºåº¦é»è©±ãããããã2æ¬¡ææ¥æ±ãã«å¤æ´ãã¦ç 颿¢ãç¶æ ã¨ã5åããã«ææ¥è¦è«ãæ¥ã¦æããããå¾ãªãã®ãç²¾ç¥çã«ã¤ããã¨ã
é½å ã¯ã©ãããéçã®ã»ããå ã«åã¾ã£ã模æ§ããã®ããéçåã®å¯è½æ§ãããä¸ççã®æ£è ãåãå ¥ãããããæ¨æ¥ã¯é½å ã§è¡ãå ´ã失ã£ãææ¥è»ã200å°ãã¾ãã£ã¦ããã ãã¨ãã¯ã¯ãã³2åæã£ã¦2é±éçµã£ã¦ãã¦ããæ®éã«è²«éãã¦ããããã¶â¦ https://t.co/cTFNuQfNol
åçï¼ãã»ã©ã®çç±ããªãéãã¯ãæ¥ç¨®ãããã¨ããå§ããã¾ã æ¥æ¬ã§æ¿èªããã¦ããmRNAã¯ã¯ãã³ã«ã¯ãæ°åã³ããã¦ã¤ã«ã¹ã¸ã®ææã»çºçã»éçåã»æ»äº¡ãªã¹ã¯ãå¤§å¹ ã«æ¸ãã广ã確èªããã¦ãã¾ããå®éã«æ°åã³ããã¦ã¤ã«ã¹ææçã«ç½¹ã£ã¦ãã¾ãããããã¯ããã«å°ããªãªã¹ã¯ã§å ç«ãç²å¾ã§ãã¾ãã ãã®ããããã»ã©ã®çç±ããªãéãã¯ãé çªãåã£ã¦ããæç¹ã§æ¥ç¨®ãããã¨ããå§ããã¾ãï¼ã¯ã¯ãã³æ¥ç¨®ã¯èªåã ãã§ãªããèªåã®å¨ãã®äººãå®ãã¨ããæç¾©ãããã¾ãï¼ã â»2023ï½2024å¹´ããããçãã«ãªãå§ãããã¯ã¯ãã³æ¥ç¨®ã徿ããããããªããæ å ±ãã«ã¤ãã¦ã¯ãã¡ããåç §ãã¦ãã ããã â»ãã®è¨äºå å®¹ã¯æ¥ç¨®ãå¼·å¶ãããã®ã§ã¯ããã¾ãããæ¥ç¨®ãããã©ããã¯å人ã®å¤æã«å§ãããã¾ããããããäºå®èª¤èªããã¨ã«å¤æãã¦ãã¾ããã¨ããªããããè¬å±ã§ãè¡ã£ã¦ããæ å ±æä¾ã対å¿ãææ¸åãããã®ã§ãã â»é常ã«é·ãã®ã§ãã
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}